MedTrace Logo

Comparison FOLFIRINOX Panitumumab vs mFOLFOX6 Panitumumab in RAS/B-RAF Wild-type Metastatic Colorectal Cancer Patients

NCT02980510 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 219

Last updated 2025-02-20

No results posted yet for this study

Summary

National trial, multicenter, randomized, phase II assessing FOLFIRINOX + Panitumumab versus mFOLFOX6 + Panitumumab in metastatic colorectal cancer patients selected by RAS and B-RAF status from circulating DNA analysis.

Evaluation of complete response rate on treatment combining FOLFIRINOX and panitumumab.

Conditions

Interventions

DRUG

Panitumumab, oxaliplatin, folinic acid, 5-fluoruracil

DRUG

Panitumumab, oxaliplatin, folinic acid, 5-fluoruracil, irinotecan

Sponsors & Collaborators

  • UNICANCER

    lead OTHER

Principal Investigators

  • Thibault MAZARD · ICM VAL D'AURELLE

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-12-31
Primary Completion
2025-12-31
Completion
2026-01-31

Countries

  • France

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02980510 on ClinicalTrials.gov